|
Drug regime gets phase II trials |
A new drug treatment regime for patients living with different forms of lymphoma is undergoing phase II clinical trials in the US, it has been announced.
Drug firms Pharmion Corporation and MethylGene are examining how two of their drugs - Pharmion's Vidaza and Methyl's MGCD0103 - perform when given to patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma. |
|
Read more...
|
|
|
Heart attack drug trials to launch |
Phase IIb trials of a medicine designed to prevent heart attacks are to begin in the spring after positive results from phase IIa trials.
Drugmaker DeCode Genetics revealed that it plans to enrol 400 subjects in a new trial designed to collect data on "its pharmacokinetic and pharmacodynamic parameters, as well as safety and tolerability". |
|
Read more...
|
|
|
Colorectal cancer enters phase II trials |
A new drug designed to treat patients with colorectal cancer is to undergo phase IIb trials later this year, it has been announced.
Nektar Therapeutics said that NKTR-102, an irinotecan, will be examined at more than 40 centres across the world in order to collect data on its safety and efficacy when used to treat patients who have solid tumours in the bowel or rectum. |
|
Read more...
|
|
|
Drug undergoes tests in two separate trials |
Two separate phase II clinical trials have been launched to test the efficacy, safety and tolerability of a new drug when it is given to patients with one of two different medical conditions.
XenPort intends to examine the performance of its XP19986 medicine when taken by patients who are suffering with gastroesophageal reflux disease (GERD) or spasticity due to spinal cord injury.
|
|
Read more...
|
|
|
US orphan drug designation given to CLL drug |
A new formulation of fludarabine phosphate has won orphan drug designation from the US Food and Drug Administration, it has been announced.
Xanthus Pharmaceuticals revealed that the tablet form of the drug, for which it holds the exclusive right to develop in the US following a deal with Schering AG, has been given the special status for use in the treatment of patients suffering with B-cell chronic lymphocytic leukemia (CLL). |
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 Next > End >>
|
| Results 1 - 9 of 46 |